Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 165-175

  Castagna, Antonella ^a   Galli, Laura ^a   Torti, Carlo ^b   Monforte, Antonella D'Arminio ^c   Mussini, Cristina ^d   Antinori, Andrea ^e   Cozzi Lepri, Alessandro ^f   Ladisa, Nicoletta ^g   De Luca, Andrea ^h   Seminari, Elena ^a   Gianotti, Nicola ^a   Lazzarin, Adriano ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

^d Infectious Diseases Clinic   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g POLICLINICO   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MALE; MIXED INFECTION; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; ITALY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77950667110     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1513     Document Type: Article

References (40)

1. + count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
2. Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
3. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J. Clin Invest 1999; 103:1391-1398.
4. 4. Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-49. (Pubitemid 38402316)
5. 5. Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment. J Acquir Immune Defic Syndr 2006; 43:433-435. (Pubitemid 44737100)
6. 6. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-1915. (Pubitemid 37070276)
7. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17:963-969.
8. 8. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413. (Pubitemid 47176633)
9. 9. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-367. (Pubitemid 34165367)
10. Keruly J, Moore R. Increases in CD4 cell count to 5 years in persons with sustained virologic suppression. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 529.
11. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446.
12. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005; 40:e101-e109.
13. 13. Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapynaive individuals with high CD4 cell count. AIDS 2007; 21:1717-1721. (Pubitemid 47237558)
14. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4:255-262.
15. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J. Acquir Immune Defic Syndr 2002; 31:20-26.
16. 16. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195. (Pubitemid 37248783)
17. 3 or greater. J. Acquir Immune Defic Syndr 2007; 45:183-192.
18. Lepri AC, Phillips AN, d'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001; 15:983-990.
19. 19. Hulgan T, Raffanti S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis 2005; 192:950-957. (Pubitemid 41266790)
20. Burcham J, Marmor M, Dubin N, et al. CD4% is the best predictor of development of AIDS in a cohort of HIVinfected homosexual men. AIDS 1991; 5:365-372.
21. 21. Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/ microL. HIV Med 2006; 7:383-388. (Pubitemid 44123249)
22. 22. Gandhi RT, Spritzler J, Chan E, et al. Effect of baselineand treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-434. (Pubitemid 44050889)
23. 23. Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. Pretreatment factors associated with 3-year (144week) virologic and immunologic responses to potent antiretroviral therapy. J. Acquir Immune Defic Syndr 2007; 44:268-277. (Pubitemid 46328342)
24. 24. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-214. (Pubitemid 28137376)
25. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998;95:1154-1159.
26. 26. Mohri H, Perelson AS, Tung K, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp Med 2001; 194:1277-1287. (Pubitemid 33055046)
27. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
28. 28. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis: 2006; 193:259-268. (Pubitemid 43113488)
29. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect Dis 2001; 183:134-137.
30. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
31. 31. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002. (Pubitemid 41266795)
32. Riddler S, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTIsparing regimens for initial treatment of HIV-1 infection -ACTG 5142. XVI International AIDS Conference. 13-18 August 2006, Toronto, ON, Canada. Abstract ThLB0204.
33. 33. Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretroviral used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-1150. (Pubitemid 43786102)
34. 34. Phenix BN, Angel JB, Mandy F, et al. Decreased HIVassociated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:559-567. (Pubitemid 30210953)
35. 35. Vlahakis SR, Bren GD, Algeciras-Schimnich A, Trushin SA, Schnepple DJ, Badley AD. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Clin Pharmacol Ther 2007; 82:294-299. (Pubitemid 47258465)
36. 36. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046. (Pubitemid 34680595)
37. + T cell count recovery in HIV type 1-infected patients Is independent of class of antiretroviral therapy. Clin Infect Dis 2008; 47:1093-1101.
38. 38. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046. (Pubitemid 39313463)
39. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
40. 40. Lin HM, Hughes M. Adjusting for regression toward the mean when variables are normally distributed. Stat Methods Med Res 1997; 6:129-146. (Pubitemid 127570360)